Iterum Therapeutics plc (ITRMF) Capital Expenditures (2017 - 2025)

Iterum Therapeutics' Capital Expenditures history runs 8 years deep, the most recent figure standing at $12000.0 for Q3 2025.

• In Q3 2025, Capital Expenditures changed N/A year-over-year to $12000.0; the TTM figure through Sep 2025 stood at $14000.0 (down 66.67% YoY), while the FY2024 annual figure was $2000.0, down 84.62% from the prior year.
• Capital Expenditures for Q3 2025 stood at $12000.0, up from $2000.0 in the prior quarter.
• The five-year high for Capital Expenditures was $45000.0 in Q4 2022, with the low at -$3000.0 in Q3 2023.
• The 4-year median for Capital Expenditures is $9500.0 (2022), against an average of $12666.7.
• The sharpest annual moves came in 2022 and 2023: Capital Expenditures surged 246.15% in 2022, then plunged 142.86% in 2023.
• Iterum Therapeutics' Capital Expenditures stood at $13000.0 in 2021, then soared by 246.15% to $45000.0 in 2022, then tumbled by 106.67% to -$3000.0 in 2023, then soared by 500.0% to $12000.0 in 2025.
• Business Quant data shows ITRMF's Capital Expenditures at $12000.0 in Q3 2025, $2000.0 in Q1 2025, and -$3000.0 in Q3 2023.